Organization
Ganzhou People's Hospital, Ganzhou, China
2 abstracts
Abstract
Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).Org: Shengjing Hospital Affiliated to China Medical University, Shenyang, China, Department of Hematology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China, Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China, Shanghai Sixth People's Hospital, Shanghai, China,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,